SPRB — Spruce Biosciences Inc

Spruce Biosciences Inc (SPRB) is a biotechnology company listed on PINK. It is led by Javier Szwarcberg M.D., M.P.H., based in 611 Gateway Boulevard, South San Francisco, CA, United States, 94080, with about 20 employees. Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure, and SPR204, a monoclonal antibody antagonist for Post-Bariatric Hypoglycemia. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. It also has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.

Latest reported SPRB revenue for 2025-09-30 was $0. Net income was -$24.3M. SPRB currently screens at market cap $3.0M.

Use this SPRB page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SPRB quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SPRB SEC filings page. Lician reads the product cache first so this HTML stays unique to Spruce Biosciences Inc even when a live quote feed is slow.